Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2010

01-07-2010 | Original Article

Digital Quantification Is More Precise than Traditional Semiquantitation of Hepatic Steatosis: Correlation with Fibrosis in 220 Treatment-Naïve Patients with Chronic Hepatitis C

Authors: Sekou R. Rawlins, Ola El-Zammar, J. Michael Zinkievich, Nancy Newman, Robert A. Levine

Published in: Digestive Diseases and Sciences | Issue 7/2010

Login to get access

Abstract

Background

Steatosis, as associated with chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD), has been considered a risk factor for development of fibrosis.

Aims

Our aims were to determine if correlations existed between the degree of steatosis and fibrosis in treatment-naïve CHC patients, and to compare the accuracy of digital image analysis with semiquantification (manual assessment) to quantify hepatic steatosis.

Methods

We studied 220 treatment-naïve, liver biopsy-proven CHC patients, including a serial biopsy sub-cohort of 37 patients with a mean interval of 3.82 years. Steatosis and fibrosis % were evaluated using digital quantification of steatosis (DQS) and fibrosis contrasted with manual assessment.

Results

Most patients had <6% steatosis measured manually and digitally. Overall, manual assessment of steatosis was 3.78 times greater than DQS. Increasing steatosis % was associated with advancing fibrosis stage, both manually and digitally. Intraobserver reliability for DQS showed higher intraclass correlation reproducibility (r = 0.98, P < 0.001) than the manual method (r = 0.81, P < 0.01). Interobserver concordance for DQS had an average measure intraclass correlation of r = 0.99. Cirrhotics were more likely than non-cirrhotics to have grade 2 steatosis.

Conclusions

Increased steatosis was associated with increased fibrosis. DQS was consistently more precise and reproducible than manual assessment of steatosis in grades 1 (1 to <6%) and 2 (6 to <34%), and may prove to be especially preferable in clinical trials of pharmacotherapeutic agents.
Literature
1.
go back to reference Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;12:1649–1657.CrossRef Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;12:1649–1657.CrossRef
2.
go back to reference Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.CrossRefPubMed Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.CrossRefPubMed
3.
go back to reference Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121.CrossRefPubMed Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121.CrossRefPubMed
4.
go back to reference Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51:89–94.CrossRefPubMed Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51:89–94.CrossRefPubMed
5.
go back to reference Hu K-Q, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147–154.CrossRefPubMed Hu K-Q, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147–154.CrossRefPubMed
6.
go back to reference Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.CrossRefPubMed Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.CrossRefPubMed
7.
go back to reference Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215–1219.CrossRefPubMed Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215–1219.CrossRefPubMed
8.
go back to reference Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained response in chronic hepatitis C patients. J Hepatol. 2004;40:484–490.CrossRefPubMed Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained response in chronic hepatitis C patients. J Hepatol. 2004;40:484–490.CrossRefPubMed
9.
go back to reference Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75–85.CrossRefPubMed Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75–85.CrossRefPubMed
10.
go back to reference Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C infection. Cancer. 2003;97:3036–3043.CrossRefPubMed Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C infection. Cancer. 2003;97:3036–3043.CrossRefPubMed
11.
go back to reference Adinolfi LE, Gambardella M, Andreanna A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364.CrossRefPubMed Adinolfi LE, Gambardella M, Andreanna A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364.CrossRefPubMed
12.
go back to reference Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, alcohol. Hepatology. 2002;36:729–736.CrossRefPubMed Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, alcohol. Hepatology. 2002;36:729–736.CrossRefPubMed
13.
go back to reference Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780–787.CrossRefPubMed Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780–787.CrossRefPubMed
14.
go back to reference Lok ASF, Everhart JE, Chung RT, et al. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007;5:245–254.CrossRefPubMed Lok ASF, Everhart JE, Chung RT, et al. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007;5:245–254.CrossRefPubMed
15.
go back to reference Lok AS, Everhart JE, Chung RT, et al. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009;49:1828–1837.CrossRefPubMed Lok AS, Everhart JE, Chung RT, et al. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009;49:1828–1837.CrossRefPubMed
16.
go back to reference Everhart JE, Lok AS, Kim H-Y, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009;137:549–557.CrossRefPubMed Everhart JE, Lok AS, Kim H-Y, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009;137:549–557.CrossRefPubMed
17.
go back to reference Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.CrossRefPubMed Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.CrossRefPubMed
18.
go back to reference Turlin B, Ramm GA, Purdie DM, et al. Assessment of hepatic steatosis: comparison of quantitative and semiquantitative methods in 108 liver biopsies. Liver Int. 2009;29:530–535.CrossRefPubMed Turlin B, Ramm GA, Purdie DM, et al. Assessment of hepatic steatosis: comparison of quantitative and semiquantitative methods in 108 liver biopsies. Liver Int. 2009;29:530–535.CrossRefPubMed
19.
go back to reference Zaitoun AM, Al Mardini H, Awad S, et al. Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C. J Clin Pathol. 2001;54:461–465.CrossRefPubMed Zaitoun AM, Al Mardini H, Awad S, et al. Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C. J Clin Pathol. 2001;54:461–465.CrossRefPubMed
20.
go back to reference Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36:1266–1272.CrossRefPubMed Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36:1266–1272.CrossRefPubMed
21.
go back to reference Boyles TH, Johnson S, Garrahan N, et al. A validated method for quantifying macrovesicular hepatic steatosis in chronic hepatitis C. Anal Quant Cytol Histol. 2007;29:244–250.PubMed Boyles TH, Johnson S, Garrahan N, et al. A validated method for quantifying macrovesicular hepatic steatosis in chronic hepatitis C. Anal Quant Cytol Histol. 2007;29:244–250.PubMed
22.
go back to reference Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.CrossRefPubMed Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.CrossRefPubMed
23.
go back to reference Lazzarini AL, Levine RA, Ploutz-Snyder R, et al. Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver Internat. 2005;25:1142–1149.CrossRef Lazzarini AL, Levine RA, Ploutz-Snyder R, et al. Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver Internat. 2005;25:1142–1149.CrossRef
24.
go back to reference Mehta P, Ploutz-Snyder R, Nandi J, et al. Diagnostic accuracy of serum hyaluronic acid, Fibrospect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2008;103:928–936.CrossRefPubMed Mehta P, Ploutz-Snyder R, Nandi J, et al. Diagnostic accuracy of serum hyaluronic acid, Fibrospect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2008;103:928–936.CrossRefPubMed
25.
go back to reference Fartoux L, Chazouillères O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41:82–87.CrossRefPubMed Fartoux L, Chazouillères O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41:82–87.CrossRefPubMed
26.
go back to reference Kurosaki M, Matsunaga K, Hirayama I, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol. 2008;48:736–742.CrossRefPubMed Kurosaki M, Matsunaga K, Hirayama I, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol. 2008;48:736–742.CrossRefPubMed
27.
go back to reference Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642.CrossRefPubMed Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642.CrossRefPubMed
28.
go back to reference Franzen LE, Ekstedt M, Kechagias S, et al. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Mod Pathol. 2005;18:912–916.CrossRefPubMed Franzen LE, Ekstedt M, Kechagias S, et al. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Mod Pathol. 2005;18:912–916.CrossRefPubMed
29.
go back to reference Krueger LE. Perceived numerosity. Percept Psychophys. 1972;11:5–9. Krueger LE. Perceived numerosity. Percept Psychophys. 1972;11:5–9.
30.
go back to reference McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30–46.CrossRef McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30–46.CrossRef
31.
go back to reference Vos PG, van Oeffelen MP, Tibosch HJ, et al. Interactions between area and numerosity. Psychol Res. 1988;50:148–154.CrossRefPubMed Vos PG, van Oeffelen MP, Tibosch HJ, et al. Interactions between area and numerosity. Psychol Res. 1988;50:148–154.CrossRefPubMed
32.
go back to reference Redden JP, Hoch SJ. The presence of variety reduces perceived quantity. J Consum Res. 2009;36:406–417.CrossRef Redden JP, Hoch SJ. The presence of variety reduces perceived quantity. J Consum Res. 2009;36:406–417.CrossRef
33.
go back to reference Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Sem Liver Dis. 2001;21:3–16.CrossRef Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Sem Liver Dis. 2001;21:3–16.CrossRef
34.
go back to reference Goodman ZD, Becker RL, Pockros PJ, et al. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007;45:886–894.CrossRefPubMed Goodman ZD, Becker RL, Pockros PJ, et al. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007;45:886–894.CrossRefPubMed
35.
go back to reference O’Brien MJ, Keating NM, Elderiny S, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Path. 2000;114:712–718.CrossRefPubMed O’Brien MJ, Keating NM, Elderiny S, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Path. 2000;114:712–718.CrossRefPubMed
36.
go back to reference Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol. 2006;4:1271–1277.CrossRefPubMed Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol. 2006;4:1271–1277.CrossRefPubMed
37.
go back to reference Kage M, Shimamutu K, Nakashima E, et al. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology. 1997;25:1028–1031.CrossRefPubMed Kage M, Shimamutu K, Nakashima E, et al. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology. 1997;25:1028–1031.CrossRefPubMed
38.
go back to reference Masseroli M, Caballero T, O’Valle F, et al. Automatic quantification of liver fibrosis: design and validation of a new image analysis method: comparison with semi-quantitative indexes of fibrosis. J Hepatol. 2000;32:453–464.CrossRefPubMed Masseroli M, Caballero T, O’Valle F, et al. Automatic quantification of liver fibrosis: design and validation of a new image analysis method: comparison with semi-quantitative indexes of fibrosis. J Hepatol. 2000;32:453–464.CrossRefPubMed
39.
go back to reference Pilette C, Rousselet MC, Bedossa P, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs. semi-quantitative scores. J Hepatol. 1998;28:439–446.CrossRefPubMed Pilette C, Rousselet MC, Bedossa P, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs. semi-quantitative scores. J Hepatol. 1998;28:439–446.CrossRefPubMed
40.
go back to reference Vuppalanchi R, Cummings OW, Saxena R, et al. Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis. A study of human liver samples. J Clin Gastroentrol. 2007;41:206–210.CrossRef Vuppalanchi R, Cummings OW, Saxena R, et al. Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis. A study of human liver samples. J Clin Gastroentrol. 2007;41:206–210.CrossRef
41.
go back to reference Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998;11:560–565.PubMed Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998;11:560–565.PubMed
42.
go back to reference Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in non alcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.CrossRefPubMed Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in non alcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.CrossRefPubMed
43.
go back to reference Belfort R, Harrison S, Brown K, et al. A placebo- controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New Eng J Med. 2006;355:2297–2307.CrossRefPubMed Belfort R, Harrison S, Brown K, et al. A placebo- controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New Eng J Med. 2006;355:2297–2307.CrossRefPubMed
Metadata
Title
Digital Quantification Is More Precise than Traditional Semiquantitation of Hepatic Steatosis: Correlation with Fibrosis in 220 Treatment-Naïve Patients with Chronic Hepatitis C
Authors
Sekou R. Rawlins
Ola El-Zammar
J. Michael Zinkievich
Nancy Newman
Robert A. Levine
Publication date
01-07-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1254-x

Other articles of this Issue 7/2010

Digestive Diseases and Sciences 7/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine